Korean J Hematol 2011; 46(1):
Published online March 31, 2011
https://doi.org/10.5045/kjh.2011.46.1.45
© The Korean Society of Hematology
1Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
2Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
Correspondence to : Correspondence to Hong Ghi Lee, M.D., Ph.D. Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, 4-12, Hwayang-dong, Gwangjin-gu, Seoul 143-729, Korea. Tel: +82-2-2030-7538, Fax: +82-2-2030-7748, mlee@kuh.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thrombotic thrombocytopenic purpura (TTP) is a critical complication of treatment with mitomycin C. We retrospectively describe the case of a patient with progressive renal cell carcinoma and mitomycin-induced TTP refractory to plasma exchange and glucocorticoids; we describe the clinical course, successful management of TTP with rituximab, and follow-up of this case. Mitomycin-induced TTP resolved completely by a total of 4 infusions of rituximab 375 mg/m2 on a weekly basis, and it took up to 12 months to obtain a platelet count of >100,000/µL. Rituximab is indicated for the treatment of mitomycin-induced TTP refractory to plasma exchange and glucocorticoids, and it could improve the patient's quality of life despite the presence of underlying malignancy.
Keywords Thrombotic thrombocytopenic purpura, Rituximab, Mitomycin, Plasma exchange
Korean J Hematol 2011; 46(1): 45-48
Published online March 31, 2011 https://doi.org/10.5045/kjh.2011.46.1.45
Copyright © The Korean Society of Hematology.
Mi Jin Hong1, Hong Ghi Lee1*, Mina Hur2, Sung Yong Kim1, Yo Han Cho1, and So Young Yoon1
1Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
2Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
Correspondence to: Correspondence to Hong Ghi Lee, M.D., Ph.D. Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, 4-12, Hwayang-dong, Gwangjin-gu, Seoul 143-729, Korea. Tel: +82-2-2030-7538, Fax: +82-2-2030-7748, mlee@kuh.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thrombotic thrombocytopenic purpura (TTP) is a critical complication of treatment with mitomycin C. We retrospectively describe the case of a patient with progressive renal cell carcinoma and mitomycin-induced TTP refractory to plasma exchange and glucocorticoids; we describe the clinical course, successful management of TTP with rituximab, and follow-up of this case. Mitomycin-induced TTP resolved completely by a total of 4 infusions of rituximab 375 mg/m2 on a weekly basis, and it took up to 12 months to obtain a platelet count of >100,000/µL. Rituximab is indicated for the treatment of mitomycin-induced TTP refractory to plasma exchange and glucocorticoids, and it could improve the patient's quality of life despite the presence of underlying malignancy.
Keywords: Thrombotic thrombocytopenic purpura, Rituximab, Mitomycin, Plasma exchange
Peripheral blood smear (Wright stain, ×1,000) showing schistocytes and spherocytes.
Change of platelet and schistocyte count during the treatment period.
Sung Hwa Bae, Sung-Hyun Kim, Soo-Mee Bang
Blood Res 2022; 57(S1): S37-S43Seungbum Lee, Je Hwan Lee, Yun suk Choi, Ji Hee Yu, Yoon Hee Chun, Won Jung Choi, Sang Su Jung
Korean J Hematol 2009; 44(3): 193-197Woojung Jeon, Young Kwon Koh, Sunghan Kang, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
Blood Res 2022; 57(1): 41-50
Peripheral blood smear (Wright stain, ×1,000) showing schistocytes and spherocytes.
|@|~(^,^)~|@|Change of platelet and schistocyte count during the treatment period.